Ken Griffin Verrica Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.56 $35,929 - $58,316	6,100 New	6,100 $44,000
Q4 2023 Feb 14, 2024	BUY	$2.93 - $7.32 $41,606 - $103,944	14,200 Added 1183.33%	15,400 $112,000
Q3 2023 Nov 14, 2023	SELL	$3.75 - $7.46 $49,500 - $98,472	-13,200 Reduced 91.67%	1,200 $4,000
Q2 2023 Aug 14, 2023	SELL	$5.32 - $6.79 $140,448 - $179,256	-26,400 Reduced 64.71%	14,400 $83,000
Q1 2023 May 15, 2023	SELL	$2.88 - $8.51 $54,432 - $160,839	-18,900 Reduced 31.66%	40,800 $265,000
Q4 2022 Feb 14, 2023	BUY	$2.09 - $3.39 $87,362 - $141,702	41,800 Added 233.52%	59,700 $164,000
Q3 2022 Nov 14, 2022	BUY	$2.17 - $4.3 $6,293 - $12,470	2,900 Added 19.33%	17,900 $52,000

17.4M

6.1K

6.3K

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.